The acquisition, which involves a concurrent licensing deal with startup Mirador, gives Jasper a chance to rebound from ...
The transition from accelerated to traditional approval is backed by robust 24-month eGFR data from the phase 3 APPLAUSE-IgAN trial.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results